Head-to-head evidence
KSI-301 vs MW02
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
MW02
Developed by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05297292 · Phase 2/3 · status unknown
This is a randomized, quadruple-blind, active-controlled Phase 2/3 trial with a clinically meaningful primary endpoint (change in visual acuity), but no results have been posted yet, so the treatment effect versus the active comparator is still unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: KSI-301's landscape · MW02's landscape